The Covid-19 pandemic upended clinical studies of new cancer drugs at many trial sites across the US. While most centers have resumed their trials, many are experiencing difficulties that have hampered their ability to run smooth operations. Staffing shortages. Salary differences between academia and industry can make nursing and clinical research coordinator jobs less appealing. Burnout also fueled a rise in the exodus, as did the broader Great Resignation. 

The clinical trial system is also facing increasing complexities in study designs, bureaucratic hurdles within academic institutions that run the trials and a rise in data and documentation requested by sponsors and their CRO counterparts. 

Endpoints News is looking to gather the experiences of trial investigators, sponsors and other stakeholders involved in the research and development of new therapies, whether for cancer or other disease areas. We are also looking to gather patient perspectives on how the clinical trial system is impacting their path to treatment.

Your responses could inform future stories. Responses may be anonymized in our reporting. Your name will only be shared with your permission. 

If you have any questions about the survey, please reach out to Associate Editor Kyle LaHucik at klahucik@endpointsnews.com.